SCHEMBL14520703

SCHEMBL14520703

Cc1cc(NCc2ccc(F)cc2)nc2nc(N)nc(N)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HRH4 Q9H3N8 2/20 0.49
HRH3 Q9Y5N1 1/20 0.49
DHFR P00374 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
KCNQ3 O43525 2/20 0.45
KCNQ2 O43526 2/20 0.45
HSD17B10 Q99714 2/20 0.43
ABCB11 O95342 1/20 0.43
ESR1 P03372 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14520705 0.87 HRH4 (0.52) HRH4DHFRPTGS2APPGHSR
SCHEMBL14520706 0.83 DHFR (0.41) MEN1KMT2AHRH4HRH3DHFR
SCHEMBL5427836 0.82 DHFR (0.42) HRH4HRH3DHFRSMN1; SMN2PTGS2
SCHEMBL14520707 0.81 DHFR (0.48) DHFRADORA3
SCHEMBL14520704 0.81 DHFR (0.43) MEN1KMT2AHRH4DHFRSMN1; SMN2
SCHEMBL14520708 0.80 IDO1 (0.41) HRH4DHFRADORA3
SCHEMBL14520712 0.79 KCNH2 (0.47) MEN1KMT2ASMN1; SMN2HSD17B10MAPK1
SCHEMBL14818974 0.77 MEN1 (0.60) MEN1KMT2AHRH4HRH3SMN1; SMN2
SCHEMBL14520713 0.76 DHFR (0.57) DHFR
SCHEMBL14520710 0.76 DHFR (0.55) DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors Ricerca Biosciences, LLC 2007-04-12 US disclosed
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors Ricerca Biosciences, LLC 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors LIG3, LIG1, NQO1 MEN1 3710/4885KMT2A 1030/4885HRH4 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.